About ClearPoint Neuro
ClearPoint Neuro is a publicly listed company based in Irvine (United States) founded in 1998. Software and hardware solutions for MRI-guided surgical planning are provided. It operates on a Direct-to-Consumer (D2C) and Professional Services model. ClearPoint Neuro has raised $17.04 million across 8 funding rounds from investors including PTC Therapeutics, Oberland Capital and Petrichor. The company has 115 employees. ClearPoint Neuro has completed 1 acquisition, including IRRAS. Its chief executive, as recorded, is Joe Burnett. Its website clearpointneuro.com draws about 12 thousand monthly visits. ClearPoint Neuro offers products and services including ClearPoint Navigation System, ClearPoint Prism Neuro Laser System, and SmartFlow Neuro Cannula. Its focus areas include Medical Devices and Neurosurgical Equipment. Its legal entity is ClearPoint Neuro, Inc. Its competitors include Caresyntax, Proprio and IMRIS Deerfield Imaging; 2 of its 3 listed competitors have raised funding.
Company details
ClearPoint Neuro is established as a global leader in device, cell, and gene therapy-enabling solutions. The company is focused on delivering precise navigation systems for brain and spine interventions. Comprehensive neurosurgical solutions are offered to healthcare professionals, emphasizing real-time imaging and intraprocedural adjustments. Support is provided for CNS drug delivery trials and translational research in gene and cell therapy. Collaboration with researchers on innovative projects is actively pursued, while patient comfort and targeted treatments are prioritized in neurosurgery advancements.
- Headquarters Irvine, United States
- Employees 115
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website clearpointneuro.com
- Social LinkedIn Facebook Instagram YouTube
- Legal Name Clearpoint Neuro Inc.
- Annual Revenue$36.97 M (USD)17.78as on Dec 31, 2025
- Net Profit-$25.54 M (USD)-35.03as on Dec 31, 2025
- EBITDA-$21.93 M (USD)-22.97as on Dec 31, 2025
- Total Equity Funding$17.04M (USD)
in 8 rounds
- InvestorsPTC Therapeutics
& 2 more
- Employee Count115
- Investments & Acquisitions
Products & Services of ClearPoint Neuro
ClearPoint Neuro offers a comprehensive portfolio of products and services, including ClearPoint Navigation System, ClearPoint Prism Neuro Laser System, and SmartFlow Neuro Cannula.
Navigation system for precise brain and spine procedures.
Laser system used for targeted neurosurgical interventions.
Cannula designed for precise drug delivery in neurosurgery.
Apps and channels of ClearPoint Neuro
its YouTube channel ClearPoint Neuro, Inc. has 539 subscribers and 30 videos.
Videos from ClearPoint Neuro
The most watched videos on ClearPoint Neuro's YouTube channel, ClearPoint Neuro, Inc. (539 subscribers). Click a video to play it here.
More on ClearPoint Neuro, Inc..
Funding Insights of ClearPoint Neuro
ClearPoint Neuro has successfully raised a total of $17.04M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.04M
- Total Rounds 8
- First Round $1.31M
(Sep 2011)
- Investors Count 3
All 8 funding rounds of ClearPoint Neuro with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | Post-IPO | β | β | ||
| Dec 2020 | $7.5M | Post-IPO | β | β | |
| May 2017 | $13.25M | Post-IPO | β | β | β |
| Dec 2015 | $5.3M | Post-IPO | β | β | β |
| Dec 2014 | $10M | Post-IPO | β | β | β |
| Feb 2013 | $11.04M | Series B | β | β | β |
| Jul 2012 | $6M | Series A | β | β | β |
| Sep 2011 | $1.31M | Unspecified | β | β | β |
3 investors in total: 3 institutional.
Investors in ClearPoint Neuro
ClearPoint Neuro has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include PTC Therapeutics, Oberland Capital and Petrichor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital. | 2013 | oberlandcapital.com | New York, United States | |
Petrichor is engaged in supporting healthcare innovation through investments. | 2018 | petrichorcap.com | New York, USA | |
Small molecule drugs for rare diseases are developed. | 1998 | ptcbio.com | South Plainfield, United States |
Investor details for ClearPoint Neuro
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ClearPoint Neuro
49 people are tracked at ClearPoint Neuro (21 in leadership, 6 in board & advisors, 22 in team); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Joe Burnett | CEO & President | Leadership |
Mazin Sabra | COO | Leadership |
Mary Mcnamara-Cullinane | VP, Regulatory Affairs | Leadership |
Jeremy Stigall | EVP & General Manager, Biologics & Drug Delivery | Leadership |
Chris Yelley | VP of Operations | Leadership |
Ernesto Salegio | VP,, Segment Leader Translational & Pre-Clinical Research | Leadership |
Lyubomir Zagorchev | VP, Clinical Science & Applications | Leadership |
Joseph M. Burnett | CEO | Leadership |
Danilo D’alessandro | CFO | Leadership |
Tanner Coleman | Director Of Operations | Leadership |
Stephanie Newton Korszen | Director Of Business Development, Biologics & Drug Delivery | Leadership |
Casey Ayala | Director, Supply Chain And Materials | Leadership |
Dennis Choi | Director Of Pre-clinical And Translational Science, Biologics And Drug Delivery | Leadership |
Shruti Gupta | Director, Oncology & Partnerships, Biologics & Drug Delivery | Leadership |
Nate Williams | Director Of Research & Development | Leadership |
Annette Ortiz | Director Of Accounting And SEC Reporting | Leadership |
Deanna Linton | Director Of Accounting | Leadership |
Megan Faulkenberry | VP, Quality | Leadership |
Devra Davis | Director, Legal And Compliance | Leadership |
Geary “Chip” Smith | Vice President Of Veterinary Medicine And Translational Science | Leadership |
29 more people are available in the full profile.
Complete people profiles for ClearPoint Neuro
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ClearPoint Neuro
ClearPoint Neuro is a publicly listed company on the NASDAQ with ticker symbol CLPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Aug 2016
- Listed onNASDAQ: CLPT
- Listed entityClearPoint Neuro Inc.
- Exchange sectorHealth technology
- ISINUS18507C1036
- Share price$9.81 (-3.82% on the day) · 2026-10-13
- Market capitalisation$299.2M
- EPS (diluted, trailing year)$-1.18
- Volume (last session)792,319
Financials of ClearPoint Neuro
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $37.0M | -$25.5M | -$21.9M |
| 2024 | $31.4M | -$18.9M | -$17.8M |
| 2023 | $23.9M | -$22.1M | -$21.0M |
| 2022 | $20.6M | -$16.4M | -$15.6M |
| 2021 | $16.3M | -$14.4M | -$12.7M |
Detailed financial statements for ClearPoint Neuro
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ClearPoint Neuro
ClearPoint Neuro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include IRRAS.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of devices for fluid control and management after surgery | irras.com | Stockholm, Sweden | 2012 | Nov 2025 | $5M |
Complete acquisition details for ClearPoint Neuro
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ClearPoint Neuro
5 dated milestones of ClearPoint Neuro across 27 years, from founding to its latest funding, stage changes and deals.
- Founded ClearPoint Neuro is founded.
- Funding First funding round of $1.3M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Acquisition Acquires IRRAS.
Competitors of ClearPoint Neuro
ClearPoint Neuro has 3 listed competitors in our database, 2 of them funded. They include Caresyntax, Proprio and IMRIS Deerfield Imaging.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| caresyntax.com | 2013 | Boston, United States | $302.5M | 64 | Surgical outcomes are enhanced via analytics and integration platform. | |
| propriovision.com | 2016 | Seattle, United States | $74.25M | 52 | Visualization systems for surgical procedures are developed using machine learning. | |
| imris.com | 2005 | Minnetonka, United States | 100 | Surgical theatres with ceiling mounted mobile imaging devices to enhance intraoperative workflow |
Detailed competitors of ClearPoint Neuro
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ClearPoint Neuro
The website of ClearPoint Neuro (clearpointneuro.com) receives about 12.3K visits a month and ranks #1,849,021 among all websites worldwide, #2,530 in Biotechnology and Pharmaceuticals.
- Monthly visits12.3K
▲ 7.7% vs previous month
- Unique visitors4.8K
per month
- Global rank#1,849,021
among all websites
- Category rank#2,530
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.3
- Average visit1 min 15 sec
- DevicesDesktop 29% Β· Mobile 71%
Websites whose visitors overlap most with ClearPoint Neuro. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| masimo.com | 100% | 170.1K | #251,325 | View details | |
| nkgenbiotech.com | 45% | 2.3K | #7,342,022 | View details | |
| realmidx.com | 44% | View details |
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as ClearPoint Neuro (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Clearpoint Neuro
Complete news archive for ClearPoint Neuro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ClearPoint Neuro
ClearPoint Neuro was founded in 1998 and raised its 1st funding round 13 years after it was founded.
ClearPoint Neuro is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Joe Burnett is the CEO of ClearPoint Neuro, as recorded in our data.
ClearPoint Neuro is a funded company, having raised a total of $17.04M across 8 funding rounds to date. The company's 1st funding round was a Unspecified of $1.31M, raised on Sep 2011.
ClearPoint Neuro has 115 employees.
Annual revenue of ClearPoint Neuro is $36.97M as on Dec 31, 2025.
ClearPoint Neuro is established as a global leader in device, cell, and gene therapy-enabling solutions. The company is focused on delivering precise navigation systems for brain and spine interventions. Comprehensive neurosurgical solutions are offered to healthcare professionals, emphasizing real-time imaging and intraprocedural adjustments. Support is provided for CNS drug delivery trials and translational research in gene and cell therapy. Collaboration with researchers on innovative projects is actively pursued, while patient comfort and targeted treatments are prioritized in neurosurgery advancements.
ClearPoint Neuro's top competitors include Caresyntax, Proprio and IMRIS Deerfield Imaging.
ClearPoint Neuro offers ClearPoint Navigation System, ClearPoint Prism Neuro Laser System, and SmartFlow Neuro Cannula.
Yes, ClearPoint Neuro is publicly traded on NASDAQ under the ticker symbol CLPT.
ClearPoint Neuro has made 1 acquisition, including IRRAS.
ClearPoint Neuro has 3 investors. Key investors include PTC Therapeutics, Oberland Capital, and Petrichor.